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Objective: We evaluated the outcome, long-term results, and factors affecting outcome of induction chemoradio-
therapy followed by surgical resection for T4 non–small cell lung cancer invading the spine.
Methods: Retrospective analysis of 23 consecutive patients undergoing radical vertebral resection for non–small
cell lung cancer invading the spine between 1996 and 2007 was performed. In most cases, induction chemora-
diotherapy consisted of cisplatin and etoposide followed by 45 Gy of radiation. Surgical resection with vertebrec-
tomy was performed en bloc in either a 1-stage or 2-stage operation. Survival was estimated by Kaplan–Meier
techniques. The log–rank comparison was used to compare groups.
Results: There were 13 men and 10 women with a median age of 61 years (range 32–75). Twenty-two patients
had induction chemoradiotherapy and 1 had induction chemotherapy alone. Vertebral resections included 6 total
vertebrectomies, 15 hemivertebrectomies, and 2 partial vertebrectomies. Complete resection was achieved in 19
(83%) patients. Two (8.7%) patients died postoperatively. Pathologic complete response was observed in 10
(43%) patients. The 3-year survival was 58% (median follow-up, 34 months). Patients who achieved pathologic
complete response or near complete response (viable tumor cells<1%) demonstrated significantly better survival
than those who did not (3-year survival, 92% vs 20%; P ¼ .006).
Conclusion: Highly selected patients with lung cancer invading the spine can potentially be cured with induction
chemoradiation therapy followed by radical en bloc resection of the tumor. A multidisciplinary operative strategy
allows a significant chance of achieving complete resection in patients requiring multilevel hemivertebrectomy or
total vertebrectomy and an appreciable cure rate.
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Surgical resection combined with chemoradiotherapy given
either preoperatively or postoperatively has become the
treatment of choice for locally advanced non–small cell
lung cancer (NSCLC).1 Advances in surgical techniques,
postoperative care, and induction chemoradiotherapy allow
aggressive resection with an acceptable mortality for pa-
tients with locally advanced stage III NSCLC that was
once considered inoperable.2
Patients with vertebral body involvement historically
have been considered to have unresectable disease.3 This
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The Journal of Thoracic and Cunfortunate group often has significant pain and neurologic
sequelae, such as pathologic fracture with paralysis, despite
best efforts with nonsurgical therapy. As innovative ap-
proaches have been developed since the late 1980s for ver-
tebral resection and spinal reconstruction,4-6 low mortality
and encouraging survival were reported in some series, lead-
ing to renewed hope for improvements in both survival
and palliation through an aggressive combined modality
approach.7-9
However, the role of induction chemoradiotherapy in the
treatment of T4 NSCLC invading the spine has yet to be
clearly defined. The primary aim of our study was to delin-
eate the impact of induction chemoradiotherapy on outcome
in patients undergoing vertebrectomy for T4 NSCLC invad-
ing the spine. We also report our experience with a 2-stage
approach for en bloc resection of tumors requiring 3-level




We retrospectively reviewed 23 consecutive patients who underwent
surgery with vertebral body resection for NSCLC with curative intent be-
tween 1996 and 2007 at the University Health Network, University of Tor-
onto. This study was approved by our institutional research ethics board at
University Health Network, University of Toronto. Eligibility criteria for
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CR ¼ complete response
CT ¼ computed tomography
MRI ¼ magnetic resonance imaging
NSCLC ¼ non–small cell lung cancer
R0 ¼ complete resection
SWOG ¼ Southwest Oncology Group Trial
radical resection included the following: (1) pathologic diagnosis of
NSCLC; (2) tumor invading the vertebral body on the basis of radiographic
findings; (3) no evidence of mediastinal node involvement on mediastino-
scopy; (4) no distant metastasis; and (5) no involvement of the spinal canal.
Patients with radiologic evidence of brachial plexus involvement at C7 or
higher or tumor involvement of the spinal cord or dura were excluded
from surgical resection. Pretreatment evaluation included physical examina-
tion, standard laboratory tests, pulmonary function tests, chest radiography,
computed tomography (CT scan) of the chest and abdomen, magnetic res-
onance imaging (MRI) of the chest and the spine, CT scan or MRI of the
brain, examination with a flexible bronchoscope, and bone scan. Mediasti-
noscopy was performed on all patients to exclude mediastinal nodal disease.
Induction Therapy
The majority of the patients (n¼ 18) received induction chemoradiother-
apy consisting of two cycles of cisplatin 50 mg/m2 on days 1 and 8 and
etoposide 50 mg/m2 on days 1 to 5 administered concurrently with radio-
therapy to a total dose of 45 Gy given in 1.8-Gy daily fractions. Three pa-
tients received the above cisplatin–etoposide chemotherapy regimen along
with concurrent radiation to a total dose of 42, 65, and 66 Gy, respectively.
The latter 2 patients receiving radiation of 65 and 66 Gy had extensive
tumors (7 and 8 cm in size, respectively, and 4 levels of vertebrae involved);
thus, the doses were designed to be maximized as curative doses in case the
tumors were found to be unresectable. One was initially given three cycles
of chemotherapy alone consisting of cisplatin and vinorelbine instead of
combined chemoradiotherapy because of the very large size of the radiation
field and concerns about radiation toxicity. Then, radiotherapy with a total
dose of 24 Gy was given sequentially because of increasing tumor-related
pain. One received chemotherapy alone with three cycles of cisplatin and
gemcitabine.
The radiation field was planned with CT scan to include the primary tu-
mor and the involved vertebra(e) with a margin. The mediastinal and hilar
lymph nodes were not included in the radiation field, but the ipsilateral
supraclavicular region was included in the radiotherapy field for superior
sulcus tumors. Between 2 and 4 weeks after induction therapy, all patients
were re-evaluated with CT scans and/or MRI of the chest and upper part of
the abdomen. Brain CT scan or MRI was also performed. Four patients un-
derwent postoperative chemotherapy with two cycles of cisplatin and etopo-
side. Postoperative adjuvant radiotherapy was not used.
Side effects seen during induction chemoradiotherapy included nausea
(grade 1, n¼ 3; grade 2, n¼ 3), anorexia (grade 1 and 2, n¼ 1 each), fatigue
(grade 1, n ¼ 2; grade 2, n ¼ 1), weight loss (grade 1, n ¼ 4), neutropenia
(grade 2, n ¼ 1), esophagitis (grade 2, n ¼ 1), and rash (grade 2, n ¼ 1). No
chemoradiotherapy-related mortality was observed.
Surgical Resection
The principles of resection were en bloc resection of the affected lung,
chest wall, nerve roots, and vertebra with wide margins. The spinal resection
was carried out through a posterolateral thoracotomy approach (anterolat-
eral spinal approach) when the tumor involved the vertebral body anterior
to the pedicle (anterior spinal elements only). After tumor resection, anterior
or anterolateral spinal stabilization and instrumented fusion were per-
formed. Tumors involving the pedicle of the vertebra (anterior and posterior
spinal elements) were approached through a combined posterior spinal ap-
proach and posterolateral thoracotomy (simultaneous or separate). Tumors
involving T1 or with extensions to the subclavian vessels were approached
anteriorly with or without resection of the proximal part of the clavicle.
Staged surgery was performed when resections were deemed difficult
and long procedures were expected; mainly when multilevel (3 levels or
more) hemivertebrectomies or total vertebrectomy was planned. The first
stage (stage I) entailed a posterior spinal procedure. Multilevel instrumenta-
tion (including pedicle screw fixation and rod stabilization) spanning prox-
imal and distal to the involved spine was placed on the side contralateral to
the tumor. On the ipsilateral side, fixation implants only were placed above
and below the tumor resection site. Posterior hemilaminectomies or com-
plete laminectomies were performed where applicable at the level of the tu-
mor. Ipsilateral nerve roots were ligated at their origin off the neural axis.
Release of the necessary posterior soft tissue (disc, ligaments, and muscles)
and bony (facet joints and transverse process) spinal elements, as well as
partial posterior vertebral body osteotomies, was performed as required.
Care was taken to preserve as much posterior paraspinal musculature as pos-
sible to maintain adequate soft tissue coverage of the spinal implants. At no
point was the tumor exposed during this part of the procedure.
Approximately 1 to 2 weeks after the stage I operation, a lateral or ante-
rior approach was performed with the patient in the lateral decubitus or su-
pine position (stage II). After localization of the tumor, the chest wall was
resected en bloc with the lobe without violating the tumor margins. The spi-
nal resection was completed by performing osteotomy (from the anterior
and/or posterior direction) of the vertebral body medial to the affected ped-
icle to obtain a clear spinal margin. Tumors invading a large portion of the
vertebral body required complete vertebral body resection. The procedure of
vertebral resection (total or hemivertebrectomy) was chosen on the basis of
preoperative CT and MRI taken after induction therapy. After complete re-
lease of the involved portion of the spinal column from the thecal sac, the en
bloc specimen of the lung, vertebral bodies, and the involved chest wall was
removed (Figure 1, A). Any margins of concern (eg, perivertebral tissues)
were checked by pathologic analysis of intraoperative frozen section in an
attempt to achieve a complete (R0) resection whenever possible. After tu-
mor resection, anterior and posterior spinal instrumentation and fusion
were completed to allow for immediate mobilization of the patient (Figure 1,
B). In the case of total vertebrectomy, a titanium mesh cage or a rib was used
to replace the resected vertebral bodies.
Statistical Analysis
Data are presented as means  standard deviation. Operative mortality
was defined as death within the first 30 days after the operation or during
the same hospitalization. Survival was measured from the date of the
combined modality therapy started until death or the last date of follow-
up (October 20, 2007). The survival curves were calculated with the
Kaplan–Meier method, and comparisons between curves were performed
by log–rank test. All data were analyzed with JMP, version 5.0 (SAS Insti-
tute, Inc, Cary, NC). Groups of continuous data were compared with the
Wilcoxon rank sum test.
RESULTS
Patient Characteristics
The preoperative patient characteristics and tumor histo-
logic types are shown in Table 1. The median age was 61
years (range, 32–75 years). All cases were clinical stage
IIIB disease (T4 N0). Poorly differentiated NSCLC could
not be subclassified in 5 cases because of the lack of more
specifically diagnostic features on preoperative cytology
and the presence of extensive necrosis and lack of residual
viable cells in the postoperative specimen. Most primary
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Stumors were in the upper lobe (87%) and were located in the
superior sulcus (n ¼ 17, 74%). The median size of the pri-
mary tumor was 7 cm (range, 4–11 cm). Regarding the
extent of spinal involvement, all cases (n¼ 23) were catego-
rized as Bilsky class D (ie, bony involvement of either ver-
tebral body or posterior elements).10 Three patients were
also entered in the Southwest Oncology Group (SWOG)
9416 (INT 0160) trial.11
Surgery
The surgical characteristics are summarized in Table 2. A
total of 14 (61%) patients underwent staged surgery. The
surgical approach was generally a posterolateral thoracot-
omy along with a posterior midline incision (65%) or
a hemi-clamshell incision combined with a posterior midline
incision (26%). Two patients were operated on through
a hemi-clamshell incision only. The average number of ver-
tebrae resected was 3.5 in the staged surgery group and 2.5
in the remaining patients. All patients undergoing total ver-
tebrectomies of more than 1 level had staged surgery. The
staged surgery group included one 2-level, two 3-level,
and one 4-level total vertebrectomy. There were 2 patients
with the subclavian artery and vein resected and 8 patients
with C8 or T1 or both C8 and T1 nerve roots resected be-
cause of subclavian vessel or brachial plexus tumor inva-
sion. All but 1 patient undergoing vertebrectomy had en
bloc resection of the tumor (96%).
Perioperative/Postoperative Course
The median duration of hospitalization was 23 days
(range, 9–86 days) in the 1-stage surgery group and 24
days (17–171 days) in the staged surgery group (stage Iþ
II). The mean operative time was 12.3  4.0 hours in the
1-stage surgery group and 12.9  3.8 hours for the second
part of the staged surgery group. In the staged surgery group,
the mean operative time for the first part of the operation was
6.4  1.8 hours. The mean blood loss and blood transfusion
during surgery were 2.7  2.3 L and 1.6  1.4 L, respec-
The Journal of Thoracic and Ctively, in the 1-stage surgery group and 4.0  1.9 L and
2.5  1.4 L, respectively, for the second part of the staged
surgery group. The mean blood loss for the first part of the
staged surgery group was 1.2  0.9 L.
A total of 11 (48%) patients had at least one major post-
operative complication including pneumonia/respiratory
failure in 7, bronchial kinking, vocal cord paralysis, spinal
device dislocation, and bronchopleural fistula in 1 each.
Two (8.7%) of the 11 patients died postoperatively because
of pneumonia and a bronchopleural fistula.
The predicted value for vital capacity was significantly
smaller in patients who had postoperative respiratory com-
plication than in those with no complications (82% 
13% vs 99%  13%, P ¼ .02). The forced expiratory vol-
ume in 1 second and diffusing capacity for carbon monoxide
were not significantly different (79%  19% vs 90% 
12%, P ¼ .2, and 56%  17% vs 79%  31%, P ¼ .2,
respectively).
Pathologic Findings
R0 resection was achieved in 19 (83%) patients. R1 re-
section was found in 4 patients. The residual site of tumor
TABLE 1. Patient characteristics













NSCLC, Non–small cell lung cancer.
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tery, the spinal dura, and the paravertebral tissue in 1 patient
each. All 4 patients had a superior sulcus tumor with multi-
ple vertebral body involvement: T1–3 in 2 patients and C7–
T3 and T1–4 in 1 patient each. Postinduction pathologic
stages in resected specimens were T0 N0 in 11 (48%) pa-
tients, T3 N0 in 1 (4%), T4 N0 in 9 (39%), and T4 N1
and T4 N2 in 1 patient each. Pathologic complete response
(CR) was observed in 10 (43%) patients and minimal micro-
scopic residual disease (viable tumor cells<1% in a largely
necrotic/fibrous tumor) was documented in 3 (13%). All 10
patients with pathologic CR had received concurrent chemo-
radiotherapy with cisplatin–etoposide and 45 Gy of radiation
before surgery. A notable discrepancy was observed be-
tween postinduction radiographic and pathologic findings
(Figure 2). The 10 patients with pathologic CR demonstrated
a postinduction residual mass involving vertebral bodies on
CT or MRI scans (stable disease in 9 and partial response
in 1).
Survival Analysis
The median follow-up period was 34 months (range, 7–
105 months). The overall 1-year and 3-year survivals for
all patients were 64% and 58%, respectively (Figure 3,
A). The median survival of all patients was 47 months. Pa-
tients with R0 resection (n ¼ 14) achieved 78% 1-year
and 72% 3-year survival, whereas those with pathologic in-
complete resection (n¼ 4) demonstrated 0% 1-year survival
(P¼ .004; Figure 3, B). Patients with pathologic CR or min-
imal microscopic residual disease demonstrated signifi-
cantly better survival than those with pathologic residual
disease (median survival not reached vs 10 months;
P ¼ .006; Figure 4). The 3-year survival of patients with
pathologic CR/minimal microscopic residual disease was
92%, whereas the 1-year survival was 25% in patients
with residual disease in the resected tumors. Of the 6 patients
with total vertebrectomy, 3 had residual disease in the re-
sected specimen and died between 7 and 9 months after their
treatment. The remaining 3 patients had pathologic CR and
are alive without clinical and radiologic tumor recurrence
21, 82, and 105 months after their treatment, respectively.
Other potential prognostic factors including sex, tumor
size ( 7 cm vs<7 cm), cell type (squamous cell carcinoma
vs others), level of vertebral involvement (T1 or higher vs
lower than T1 level), and total amount of red blood cell
transfusion ( 2 L vs<2 L) were not significant prognostic
factors for survival after surgery.
Local tumor control after R0 resection was excellent with
only one local recurrence (4%). Distant recurrence was ob-
served in 3 (13%) patients, including lung (n ¼ 2), bone
TABLE 2. Surgical characteristics
One-stage (n ¼ 9) Staged (n ¼ 14)




Type of lung resection
Lobectomy 8 12
Wedge resection 1 1
Pneumonectomy — 1
Type of vertebral resection
Total ( partial) 2 4
Hemi ( partial) 5 10
Partial 2 —





*Posterior spinal approach was added whenever necessary.
FIGURE 2. A, Computed tomographic scan demonstrating a tumor in the right upper lobe extending into the vertebral body. B, Signs of vertebral body
invasion remained after induction chemoradiotherapy, but no viable tumor cells were observed in the resected specimen (pathologic CR).
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curred within 1 year after surgery.
DISCUSSION
The current standard of care for locally advanced NSCLC
is a combination of chemotherapy and radiotherapy, given
either concurrently or subsequently.12 However, there are
some subsets of patients, in particular those with T4 N0–1
tumors, for whom surgery may have a vital role to play.1
Our study clearly shows that induction chemoradiotherapy
followed by en bloc radical resection and vertebrectomy is
feasible and offers excellent local tumor control and promis-
ing long-term survival results. Rusch and associates11 have
recently reported the mature survival results of surgical re-
section preceded by induction chemoradiotherapy for T3–4
N0–1 superior sulcus NSCLC (SWOG 9416). The authors
concluded that concurrent induction chemoradiotherapy
FIGURE 3. A, Overall survival for all patients who underwent induction
chemoradiotherapy followed by radical vertebrectomy (n¼ 23). B, Survival
according to the completeness of resection (complete versus incomplete
resection).
The Journal of Thoracic and Cwas associated with high rates of R0 resection with 83
(94%) of 88 patients who underwent surgery achieving
R0 resection. Pathologic CR or minimal microscopic resid-
ual disease was seen in 61 (56%) resected specimens. In our
study, the pathologic CR (or minimal microscopic residual
disease) rate was comparable (57%) in patients who under-
went the same concurrent induction chemoradiotherapy reg-
imen of cisplatin and etoposide. Given that pathologic CR is
a crucial prognostic factor as shown both in SWOG 9416
and in our study, effective induction treatment is of impor-
tance in surgical candidates who have locally advanced
NSCLC, including those tumors invading the vertebral
body. However, T4 N2 disease is quite different from T4
N0–1 in prognosis. Patients with N2 and N3 disease in the
SWOG series had 5-year survivals of only 13% and 15%.
We carefully excluded N2 disease by mediastinoscopy
before induction therapy in candidates for surgical resection.
Some groups have reported innovative strategies of induction
chemotherapy with hyperfractionated accelerated radio-
therapy,13-17 induction platinum-based chemoradiotherapy
combined with either third-generation15,17 or oral chemother-
apeutic agents,18 or induction chemotherapy with concurrent
dose-escalated radiotherapy19 for locally advanced NSCLC
to obtain increased tumor response and improved survival
(Table E1). Furthermore, improvements in dose-localization
techniques such as intensity-modulated radiation therapy or
image-guided radiation therapy may improve the local re-
sponse rate as well as decrease radiation toxicity.20
Our median survival of 47 months and 54% 3-year sur-
vival compare favorably with the results in patients with
pathologically confirmed T4 N0–1 NSCLC who received
definitive chemoradiotherapy without surgery (median sur-
vival, 20 months; 3-year survival, 22%) reported by Albain
FIGURE 4. Survival according to the pathologic response in the resected
specimen in patients with R0 resection (pathologic CR, n ¼ 10; near CR*,
n¼ 3; pathologic residual disease, n¼ 6). *Viable tumor cells less than 1%
in a resected tumor.
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Sand coworkers.21 The chemoradiotherapy protocol used in
their study was the same as ours, in which chemotherapy
consisted of two cycles of cisplatin and etoposide with 45
Gy of concurrent radiotherapy. In the absence of progressive
disease, radiotherapy continued to a total dose of 61 Gy and
two more cycles of chemotherapy were administered after
completion of radiation.
Staged surgery is an integral part of our treatment strategy
of en bloc vertebrectomy, especially in patients requiring
a multilevel total vertebrectomy. We started using staged sur-
gery in 2003 and since then have resected three or more ver-
tebrae in 13 (93%) of 14 patients, of whom 4 received
a multilevel total vertebrectomy. Inasmuch as the first-stage
operation does not necessitate performing a thoracotomy, re-
covery from the operation is generally quite rapid, despite the
blood loss related to the spinal procedures. Thus, we were able
to perform the second part of the operation to complete the en
bloc resection 1 week after the first-stage operation without
encountering problematic adhesive changes at the site of op-
eration. The longer operation time and greater blood loss seen
in the staged surgery group in general reflected the more ad-
vanced cases that were selected for the staged procedures
for en bloc resection. In our series, en bloc R0 tumor resection
appeared to be critical inasmuch as favorable outcomes were
obtained even in patients requiring multilevel total vertebrec-
tomy when en bloc R0 resection was successfully performed.
Outcomes of previously reported series of vertebral resection
for NSCLC and ours are summarized in Table 3.
In our series, only 1 patient required reoperation for
a spine-related complication (spinal device dislocation).
Some have argued that preoperative radiotherapy adds little
to the cure and may increase local tissue fragility9,22; how-
ever, on the basis of our results and those of others,7 secure
reconstruction can be achieved with appropriate anterior fix-
ation and extended posterior fixation, both above and below
the levels of resected vertebrae, even after induction chemo-
radiotherapy.
There are some limitations of this study. Inasmuch as this is
a retrospective, nonrandomized, single-institutional study
with highly selected patients over the past 10 years, a solid
conclusion cannot be drawn; however, a randomized, large-
scale study is not realistic owing to the small numbers of
such patients. In addition, formal quality-of-life assessment
of these patients would better refine the roles of this aggressive
treatment protocol in a group of patients who would otherwise
have a dismal outcome, not only in terms of poor survival, but
also significant pain and in many cases paralysis resulting
from local tumor progression.
In conclusion, induction chemoradiotherapy followed by
staged en bloc vertebral resection is a treatment option for
selected patients with NSCLC invading the spine. The en
bloc resection can be performed safely with a relatively
low mortality rate. Although the short-term morbidity was
high, most complications were manageable. The morbidity
seems to be justifiable in view of the long-term results ob-
served at our institution, although longer-term follow-up is
required. However, we emphasize that this sort of treatment
should only be undertaken by a dedicated team of thoracic
and spinal surgeons in an institution that has the necessary
postoperative support to manage the immediate postopera-
tive complications. Inasmuch as pathologic CR is a strong
indicator of favorable prognosis, refinements of induction
therapy may be important in further improving outcomes
in this group of patients in the future.
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G
T
STABLE E1. Pathologic complete response rate in selected recent induction chemoradiation protocols for patients with stage IIIB NSCLC
Author (y) n* Regimen Pathologic CRy (%)
Eberhardt13 (1998) 42 (8) Cis/Eto with Hf-RT (45 Gy) 36
Grunenwald14 (2001) 40 (6) Cis/5FU/Vin with Hf-RT (42 Gy) 17
DeCamp15 (2003) 27 (3) Cis/Pac with Hf-RT (30 Gy) 11z
Ichinose18 (2003) 27 (4) Cis/UFT with RT (40 Gy) 24
Trodella16 (2004) 35 (30) Carb or Cis/5FU with RT or Hf-RT (50.4 Gy) 29z
Sonnet19 (2004) 10 (4) Platinum-based with RT (59.6-66.6 Gy) 30
Marra17 (2007) 31 (4) Cis/Eto or Cis/Pac with Hf-RT (45 Gy) 45x
Rusch11 (2007) 32 (32) Cis/Eto with RT (45 Gy) 36x
Anraku (2008) 23 (23) Cis/Eto with RT (42-66.6 Gy) 43
*(Cases of T4 N0, 1 in reported series.) CR, Complete response; Cis, cisplatin; Carb, carboplatin; Eto, etoposide; Pac, paclitaxel; UFT, oral uracil/tegafur; 5FU, 5-fluorouracil; Vin,
vinblastine; RT, radiotherapy; Hf-RT, hyperfractionated radiotherapy. yPercent in patients with surgical resection. zClinical stage IIIA included. xClinical stage IIB (T3) and IIIA
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